AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Key facts
- Where
- Bangkok, Chiang Mai, Pathum Thani, and Songkhla, ThailandSee the 5 sites
- Phase
- Phase 3
Where in Thailand
- Ramathibodi HospitalBangkok, ThailandNo longer taking part
- Siriraj Institute of Clinical ResearchBangkok, ThailandNo longer taking part
- Maharaj Nakorn Chiang MaiChiang Mai, ThailandNo longer taking part
- Thammasat Hospital_CRCPathum Thani, ThailandNo longer taking part
- Songklanagarind HospitalSongkhla, ThailandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07668401
- Record updated
- 24 August 2026
- Original description
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent.
Exclusion: Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus; Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.